As of November 7, 2026, Olema Pharmaceuticals, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 29, 2026 to October 15, 2026, naming 1 appointment and 1 departure. The latest filing names Gorjan Hrustanovic, leaving (Form 8-K, October 15, 2026).
Who owns Olema Pharmaceuticals, Inc.?
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Olema Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: Gorjan Hrustanovic · Effective: 2026-10-14 · 8-K, 2026-10-15
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-08-13
- · In / out: In · Person: Prakash Raman · Role: Director · Effective: 2026-04-28 · 8-K, 2026-04-29
Olema Pharmaceuticals, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-29 to 2026-10-15. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Olema Pharmaceuticals, Inc. files it.
Also on the record for Olema Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 16, 2026 | Stake report, Schedule 13D/A, by BIOTECHNOLOGY VALUE FUND L P | 9.8% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 13.8% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 7.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Bain Capital Life Sciences Opportunities IV, L.P. | 8.15% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 8.2% of the class | 5%+ stakes | Source |
| March 20, 2026 | Stake report, Schedule 13G, by Raymond Debbane | 5.1% of the class | 5%+ stakes | Source |
| March 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 12.5% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Bain Capital Life Sciences Opportunities IV, L.P. | 9.99% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 8.4% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | — | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G, by FMR LLC | 6.3% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by JANUS HENDERSON GROUP PLC | 5.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Olema Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Olema Pharmaceuticals, Inc. and the records around it.
Olema Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Bain Capital Life Sciences Opportunities IV, L.P. also filed stake reports on 1 other company: ADC Therapeutics SA (Oct 2026)
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026), Stoke Therapeutics, Inc. (Sep 2026)
Watch Olema Pharmaceuticals, Inc.
Get an email when Olema Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Olema Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Olema Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Olema Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 13 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-15 | Out | 2026-10-14 | 8-K, 2026-10-15 | ||
| 2026-08-13 | Reported | not named in the filing | 8-K, 2026-08-13 | ||
| 2026-04-29 | In | Director | 2026-04-28 | 8-K, 2026-04-29 |
Who leads Olema Pharmaceuticals, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Prakash Raman, appointed, effective 2026-04-28 (filed 2026-04-29).
New leaders reset buying decisions — get the Full Report on Olema Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Olema Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Director at Olema Pharmaceuticals, Inc.Every change, in the filing's words
Departing: Gorjan Hrustanovic, effective 2026-10-14
On October 12, 2026, Dr. Gorjan Hrustanovic notified Olema Pharmaceuticals, Inc. (the "Company") of his decision to resign from the Company's Board of Directors (the "Board"), effective October 14, 2026.
- Dr. Hrustanovic also resigned from the Compensation Committee of the Board (the "Compensation Committee") and the Science and Technology Committee of the Board (the "Science and Technology Committee").
- Dr. Hrustanovic's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- The Company thanks Dr. Hrustanovic for his service and contributions to the Company and the Board.
- On October 15, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Dr. Prakash Raman to the Compensation Committee and to the Science and Technology Committee, in each case effective October 15, 2026.
Reported
On August 13, 2026, Olema Pharmaceuticals, Inc. (the "Company") announced the appointment of Jason O'Byrne as the Company's Chief Financial Officer, principal financial officer and principal accounting officer, which was approved by the Board of Directors of the Company (the "Board") on July 28, 2026 and effective as of August 11, 2026 (the "Effective Date").
- Mr. O'Byrne, age 58, served as Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc., a biopharmaceutical company, from October 2024 to August 2026.
- Prior to that, Mr. O'Byrne served as Chief Financial Officer of Caribou Biosciences, Inc., a biopharmaceutical company, from 2021 to 2024.
- Previously, Mr. O'Byrne served as Vice President, and subsequently, Senior Vice President of Finance at Audentes Therapeutics, Inc., a biotechnology company, from 2019 to 2021, including through its acquisition by Astellas Pharma in 2020.
- Earlier in his career, Mr. O'Byrne spent 13 years at Genentech, Inc., a biotechnology company, and its parent company the Roche Group, a global healthcare company, where he held finance leadership positions of increasing responsibility, including Vice President, Head of Finance for Roche Asia-Pacific and Vice President, Global Head of Finance for Product Development and Product Strategy.
- Mr. O'Byrne received a B.A.Sc. in mechanical engineering from the University of British Columbia and an M.B.A. in finance, with distinction, from New York University's Stern School of Business.
- In connection with his appointment, Mr. O'Byrne and the Company entered into an offer letter (the "Offer Letter").
- Pursuant to the Offer Letter, Mr. O'Byrne's initial annualized base salary is $545,000.
Appointed: Prakash Raman, Director, effective 2026-04-28
On April 27, 2026, upon recommendation from the Nominating and Corporate Governance Committee (the "Nominating Committee") of the Board of Directors (the "Board") of Olema Pharmaceuticals, Inc. (the "Company"), the Board appointed Dr. Prakash Raman to the Board as a Class II director, effective April 28, 2026 (the "Effective Date").
- Dr. Raman's term will expire, along with the terms of the other Class II directors, at the Company's annual meeting of stockholders in 2028.
- The Board has determined that Dr. Raman qualifies as an independent director under the independence requirements set forth under Rule 5605(a)(2) of the Nasdaq Rules and listing standards.
- The Initial Grant will vest in a series of 36 successive equal monthly installments over the three-year period measured from the date of grant, subject to Dr. Raman's continuous service through each applicable vesting date.
- The Partial Year Grant will vest in full on June 11, 2026, subject to Dr. Raman's continuous service through such date.
- Each grant is subject to the terms and conditions of the Company's 2020 Equity Incentive Plan and its related agreements.
- The Company has also entered into its standard form of indemnification agreement with Dr. Raman.
Tools for this story
Each opens in a new tab, filled in for Olema Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.